Abstract: The present invention relates to insecticidal formulations for vector and pest control with increased contact efficacy, more particularly to insecticidal active ingredient—matrix particles and insecticidal compositions comprising such insecticidal active ingredient—matrix particles, as well as to methods and uses of such insecticidal formulations.

Abstract: The present invention relates cannabinoid chewing gums with improved flavor perception. The cannabinoid chewing gums include water-soluble chewing gum ingredients and water-insoluble gum base, one or more cannabinoids with an off-note taste, one or more high intensity sweeteners in an amount of 0.05 to 0.9% by weight of the cannabinoid chewing gum that partly serves to mask the taste of said unbound cannabinoids, one or more flavoring ingredients in an amount of 0.01 to 5% by weight of the cannabinoid chewing gum that in combination with the one or more high intensity sweeteners partly serves to mask the taste of said unbound cannabinoids, wherein the one or more cannabinoids is located in close proximity with the one or more high intensity sweeteners as well as the one or more flavoring ingredients.

Abstract: Quat-free surface treatment powders comprising a peroxide source, an acyl group donor and an alkalinity source are used to disinfect and/or sanitize hard surfaces. The surface treatment powders can be applied to a hard surface and left there for a period of time. The surface treatment powders are ambient moisture activated, which means that they can generate peracetic acid when a portion or all of the powder that is on the hard surface adsorbs water from the atmosphere. In addition or alternatively, the surface treatment powders are activated, i.e., generate peracetic acid through the incidental or purposeful addition of liquid thereto.

Abstract: Disclosed herein are safe and effective ways to perform dermal filling procedures. Specifically, the present disclosure relates to agarose-based dermal fillers with advanced rheological properties which are easier to inject and disperse compared to HA based dermal fillers. The present disclosure further relates to the methods and kits to provide additional safety advantages over other injectables, as the agarose-based dermal fillers can be dispersed quickly to prevent injury to a patient.

Abstract: The invention relates to pharmaceutical compositions comprising one or more benzodiazepine drugs for nasal administration, methods for producing and for using such compositions.

Abstract: The present invention provides a polysaccharide carbon nanogel exhibiting antitumor efficacy prepared by carbonizing the polysaccharide utilizing dry heating. The polysaccharide carbon nanogel comprises a graphene-like nanosheet and a polysaccharide, which are complexed to form a cross-linked supramolecular structure. The polysaccharide carbon nanogels has an exceptional polyphenolic structure and high antimetastatic activity, which can become a promising anti-tumor drug.

Abstract: Antimicrobial preservative compositions that can be incorporated in products to be preserved are disclosed herein. The disclosed compositions include immobilized biocidal enzymes, such as cross-linking enzymes or active enzymes falling into the zymogen-class, for the purpose of modifying amino acid residues on a protein or binding a molecule of interest to a protein. The compositions include enzymes that are immobilized on a polymeric solid support, which improve the shelf life of the enzyme and protect the enzyme from auto-cross-linking or other deterioration over extended storage periods. Also disclosed are methods of increasing the self-like of products, such as personal care, household and industrial products, by incorporating an effective amount of the disclosed compositions into the product.

Abstract: Disclosed herein are antimicrobial materials comprising a carbohydrate-templated microgel and a plurality of metal ions complexed thereto. The carbohydrate-templated microgel comprises a network copolymer molecule comprising a monoacrylate monomer, a crosslinking monomer, and a ligand monomer and wherein the microgel is prepared by the copolymerization of the monoacrylate monomer, the crosslinking monomer, and the ligand monomer in the presence of a carbohydrate or a carbohydrate derivative. The microgels have antimicrobial activity and allow for implementation of multiple, simultaneous mechanisms of antimicrobial action.

Abstract: The invention provides methods and polymer compositions for treating ocular disorders, where the methods and compositions comprise polymer that can form a hydrogel in the eye of a subject. The hydrogel is formed by reaction of (i) a nucleo-functional polymer that is a biocompatible polymer, such as a thiolated hyaluronic acid polymer, containing a plurality of thio-functional groups —R1—SH wherein R1 is hydrolyzable and (ii) an electro-functional polymer that is a biocompatible polymer, such as a poly(ethylene glycol) polymer, containing at least one thiol-reactive group.

Abstract: Cosmetic formulation with deodorant activity for topical application including vitamin E or an ester thereof, starch, sodium bicarbonate, zinc oxide and a cosmetically acceptable carrier is disclosed. The vitamin E ester is preferably alpha-tocopherol acetate, n-propionate or linoleate and the vitamin E or ester thereof and is present in an amount of 5-40% by weight of the weight of the formulation.

Abstract: The present invention relates to a sensory emulsifying composition, in particular for cosmetic use, capable of obtaining a liquid oil-in-water-type emulsion comprising at least one cyclodextrin in the form of solid particles, said particles having a volumetric average particle size d(4,3), measured by laser granulometry, of between 2 and 20 ?m, preferably between 3 and 12 ?m, and more preferably between 4 and 8 ?m, and at least one emulsifier of natural origin selected from water-in-oil emulsifiers, having a hydrophilic-lipophilic balance (HLB) of less than 8.

Abstract: This invention relates to oral care compositions, for example comprising a salt of a basic amino acid having a pH in solution of less than 7.5, an abrasive having a pH in solution of less than 7.5, and a fluoride ion source, and an acid selected from the group consisting of: a carboxylic acid (e.g., citric acid, lactic acid, glycolic acid, acetic acid, succinic acid, or fumaric acid), and an inorganic acid, wherein the inorganic acid is not phosphoric acid or sulfuric acid (e.g., wherein the inorganic acid is hydrochloric acid or sodium acid pyrophosphate), and to methods of using and of making these compositions.

Abstract: The invention also relates to processes for producing abuse deterrent pharmaceutical compositions comprising highly pure amphetamine and amphetamine-class compounds resulting from the synthesis of chiral and racemic amphetamine derivatives by stereospecific, regioselective cuprate addition reaction with aziridine phosphoramidate compounds, and to methods of manufacturing, delivering, and using the amphetamine compounds resulting from the synthesis of chiral and racemic amphetamine derivatives by stereospecific, regioselective cuprate addition reaction with aziridine phosphoramidate compounds.

Abstract: The disclosure relates generally to polyglutamated antifolates, formulations containing liposomes filled with the polyglutamated antifolates, methods of making the polyglutamated antifolates and liposome containing formulations, and methods of using the polyglutamated antifolates and liposome containing formulations to treat hyerproliferative disorders (e.g., cancer) and disorders of the immune system (e.g., an autoimmune disease such as rheumatoid arthritis).

Abstract: A method, and formulations for the method, for the treatment of hair loss is herein described. Typically, the method involves applying an exosome-based skincare product to skin affected by hair loss, such as the skin of the scalp. The exosome-based skincare product contains exosomes produced by and excreted from human umbilical mesenchymal stem cells cultured in vitro under specific conditions and then contained within a solvent. The hair loss may be caused by androgenic alopecia, alopecia areta, or telogen effulvium.

Abstract: A biological hair shape change composition including a macromolecular component, a small molecular component and an alkali agent component is provided. The macromolecular component includes a protease belonging to the class of alkaline proteases, and the small molecular component includes a peptide with reduction activity. Both the macromolecular component and the small molecular component are obtained from a fermentation product of Bacillus licheniformis and a keratin and/or keratin polymer-containing medium. Molecular weights of ingredients in the macromolecular component are greater than or equal to 3 kDa and are 3-1000 kDa, and molecular weights of ingredients in the small molecular component are less than 3 kDa and are 0.01-2.99 kDa.

Abstract: Compositions and methods for targeted delivery of active agents to cells are provided. The compositions comprise a wholly or partially double-stranded synthetic DNA carrier, and an active agent intercalated in double-stranded portions of the DNA carrier. The DNA carrier may also be linked to a targeting agent. The compositions are useful for delivering an active agent into a targeted cell type, for example a cytotoxic agent.

Abstract: Leave-on oral care compositions having good spreadability and improved retention property are provided for promoting Gum Health of a user. Leave-on oral care compositions can comprise a hyaluronic acid or a salt thereof, a polyacrylic acid as a mucoadhesive polymer, and an additional polymer.

Abstract: The disclosure relates generally to polyglutamated antifolates, formulations containing liposomes filled with alpha or D-gamma polyglutamated antifolates, methods of making the polyglutamated antifolates and liposome containing formulations, and methods of using polyglutamated antifolates and liposome containing formulations to treat hyerproliferative disorders (e.g., cancer) and disorders of the immune system (e.g., an autoimmune disease such as rheumatoid arthritis).

Abstract: The disclosure relates generally to polyglutamated antifolates, formulations containing liposomes filled with alpha or D-gamma polyglutamated antifolates, methods of making the polyglutamated antifolates and liposome containing formulations, and methods of using polyglutamated antifolates and liposome containing formulations to treat hyerproliferative disorders (e.g., cancer) and disorders of the immune system (e.g., an autoimmune disease such as rheumatoid arthritis).